# Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood

> **NCT00639158** · PHASE3 · COMPLETED · sponsor: **Abbott** · enrollment: 543 (actual)

## Conditions studied

- Dyslipidemias
- Coronary Heart Disease
- Combined (Atherogenic) Dyslipidemia
- Mixed Dyslipidemia

## Interventions

- **DRUG:** ABT-335
- **DRUG:** placebo
- **DRUG:** atorvastatin
- **DRUG:** ezetimibe

## Key facts

- **NCT ID:** NCT00639158
- **Lead sponsor:** Abbott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2008-10
- **Final completion:** —
- **Target enrollment:** 543 (ACTUAL)
- **Last updated:** 2011-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00639158

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00639158, "Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00639158. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*